Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

PICAROS – Acalabrutinib RWE auf 1L CLL in Spanien (PICAROS)

3. November 2026 aktualisiert von: AstraZeneca

Nicht-interventionelle Kohortenstudie an Patienten mit chronischer lymphatischer Leukämie, die zuvor unbehandelt waren oder BTKi der ersten Generation nicht vertrugen, zur Beschreibung des Erstlinieneinsatzes von Acalabrutinib und seiner praktischen Ergebnisse in Spanien: die PICAROS-Studie

This is a multicenter non-interventional study (NIS) of patients with CLL treated with first-line acalabrutinib according to routine clinical practice in Spain. It included an initial cohort of patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression (cohort 1). This cohort is complemented with the addition of another regarding the first-line fixed-duration acalabrutinib use with venetoclax in routine practice (cohort 2).

Studienübersicht

Status

Rekrutierung

Bedingungen

Detaillierte Beschreibung

This is a multicenter, non-interventional study (NIS) based on ambispective (including retrospective and/or prospective) real-world data collection of patients with CLL who received treatment with acalabrutinib for the first time in Spain.

It included an initial cohort of patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression (cohort 1). This cohort is complemented with the addition of another regarding the first-line fixed-duration acalabrutinib use with venetoclax in routine practice (cohort 2).

For the cohort 1, the start of acalabrutinib treatment (index date) was prior to the first site initiation visit. For both cohorts 1 and 2, the clinical decision of starting patient on acalabrutinib has to independently occur prior to the patient inclusion into this study. Patients' eligibility for study inclusion is regardless of their current status of acalabrutinib therapy, for example, patients already deceased or discontinued therapy are still eligible to be included into this study. Patient data will be collected both retrospectively and/or prospectively up to approximately 32 months from the first site initiation visit for cohort 1, and approximately 25 months after the inclusion of the last patient in the cohort 2. For patients who received acalabrutinib therapy and have deceased, only retrospective medical chart review will be conducted.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

315

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Andalusia
      • Almería, Andalusia, Spanien, 4009
        • Rekrutierung
        • Research Site
      • Córdoba, Andalusia, Spanien, 14004
        • Rekrutierung
        • Research Site
      • Granada, Andalusia, Spanien, 18014
        • Rekrutierung
        • Research Site
      • Jaén, Andalusia, Spanien, 23007
        • Aktiv, nicht rekrutierend
        • Research Site
      • Marbella, Andalusia, Spanien, 29603
        • Aktiv, nicht rekrutierend
        • Research Site
      • Málaga, Andalusia, Spanien, 29010
        • Aktiv, nicht rekrutierend
        • Research Site
      • Seville, Andalusia, Spanien, 41013
        • Rekrutierung
        • Research Site
    • Aragon
      • Zaragoza, Aragon, Spanien, 50009
        • Rekrutierung
        • Research Site
      • Zaragoza, Aragon, Spanien, 50009
        • Aktiv, nicht rekrutierend
        • Research Site
    • Balearic Islands
      • Palma de Mallorca, Balearic Islands, Spanien, 7010
        • Aktiv, nicht rekrutierend
        • Research Site
      • Palma de Mallorca, Balearic Islands, Spanien, 7198
        • Aktiv, nicht rekrutierend
        • Research Site
    • Basque Country
      • Donostia / San Sebastian, Basque Country, Spanien, 20014
        • Zurückgezogen
        • Research Site
      • Galdakao, Basque Country, Spanien, 48960
        • Zurückgezogen
        • Research Site
    • Canary Islands
      • Las Palmas de Gran Canaria, Canary Islands, Spanien, 35016
        • Aktiv, nicht rekrutierend
        • Research Site
      • Las Palmas de Gran Canaria, Canary Islands, Spanien, 35019
        • Aktiv, nicht rekrutierend
        • Research Site
      • San Cristóbal de La Laguna, Canary Islands, Spanien, 38320
        • Rekrutierung
        • Research Site
    • Cantabria
      • Santander, Cantabria, Spanien, 39008
        • Aktiv, nicht rekrutierend
        • Research Site
    • Castille and León
      • Salamanca, Castille and León, Spanien, 37007
        • Aktiv, nicht rekrutierend
        • Research Site
      • Segovia, Castille and León, Spanien, 40002
        • Aktiv, nicht rekrutierend
        • Research Site
      • Valladolid, Castille and León, Spanien, 47003
        • Aktiv, nicht rekrutierend
        • Research Site
      • Valladolid, Castille and León, Spanien, 47012
        • Aktiv, nicht rekrutierend
        • Research Site
    • Castille-La Mancha
      • Guadalajara, Castille-La Mancha, Spanien, 19002
        • Rekrutierung
        • Research Site
      • Toledo, Castille-La Mancha, Spanien, 45004
        • Aktiv, nicht rekrutierend
        • Research Site
    • Catalonia
      • Barcelona, Catalonia, Spanien, 8003
        • Aktiv, nicht rekrutierend
        • Research Site
      • Barcelona, Catalonia, Spanien, 8025
        • Aktiv, nicht rekrutierend
        • Research Site
      • Barcelona, Catalonia, Spanien, 8035
        • Aktiv, nicht rekrutierend
        • Research Site
      • Barcelona, Catalonia, Spanien, 8036
        • Aktiv, nicht rekrutierend
        • Research Site
      • Granollers, Catalonia, Spanien, 8402
        • Aktiv, nicht rekrutierend
        • Research Site
      • L'Hospitalet de Llobregat, Catalonia, Spanien, 8908
        • Aktiv, nicht rekrutierend
        • Research Site
      • Lleida, Catalonia, Spanien, 25198
        • Aktiv, nicht rekrutierend
        • Research Site
      • Terrassa, Catalonia, Spanien, 8221
        • Aktiv, nicht rekrutierend
        • Research Site
    • Galicia
      • Ourense, Galicia, Spanien, 32005
        • Rekrutierung
        • Research Site
      • Santiago de Compostela, Galicia, Spanien, 15706
        • Aktiv, nicht rekrutierend
        • Research Site
      • Vigo, Galicia, Spanien, 36312
        • Rekrutierung
        • Research Site
    • Madrid
      • Madrid, Madrid, Spanien, 28006
        • Rekrutierung
        • Research Site
      • Madrid, Madrid, Spanien, 28031
        • Aktiv, nicht rekrutierend
        • Research Site
      • Madrid, Madrid, Spanien, 28034
        • Aktiv, nicht rekrutierend
        • Research Site
      • Madrid, Madrid, Spanien, 28905
        • Aktiv, nicht rekrutierend
        • Research Site
      • Madrid, Madrid, Spanien, 28911
        • Aktiv, nicht rekrutierend
        • Research Site
      • Madrid, Madrid, Spanien, 28040
        • Rekrutierung
        • Research Site
      • Madrid, Madrid, Spanien, 28041
        • Rekrutierung
        • Research Site
      • Madrid, Madrid, Spanien, 28046
        • Rekrutierung
        • Research Site
      • Majadahonda, Madrid, Spanien, 28222
        • Aktiv, nicht rekrutierend
        • Research Site
    • Murcia
      • El Palmar, Murcia, Spanien, 30120
        • Aktiv, nicht rekrutierend
        • Research Site
      • Murcia, Murcia, Spanien, 30008
        • Rekrutierung
        • Research Site
    • Principality of Asturias
      • Oviedo, Principality of Asturias, Spanien, 33011
        • Aktiv, nicht rekrutierend
        • Research Site
    • Valencia
      • Alicante, Valencia, Spanien, 3010
        • Rekrutierung
        • Research Site
      • Valencia, Valencia, Spanien, 46010
        • Aktiv, nicht rekrutierend
        • Research Site
      • Valencia, Valencia, Spanien, 46014
        • Aktiv, nicht rekrutierend
        • Research Site
      • Valencia, Valencia, Spanien, 46026
        • Aktiv, nicht rekrutierend
        • Research Site

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

The study aims to include approximately 315 patients in the cohort 1 and 103 patients in the cohort 2 who started acalabrutinib for the first time for the treatment of their CLL. To minimize selection biases, all patients (alive or deceased) identified on acalabrutinib will be eligible for inclusion into the study. These patients will be included from approximately 50 hospitals distributed throughout Spain.

Beschreibung

Inclusion Criteria:

  • Age ≥18 years old at starting acalabrutinib treatment.
  • Diagnosis of CLL.
  • Start of acalabrutinib treatment (index date) as per the CLL SmPC:
  • in treatment-naïve CLL patients or those switching in first-line between first-generation BTK inhibitor to acalabrutinib due to intolerance in absence of progression according to routine clinical practice within the year before the first site initiation visit (cohort 1).
  • in treatment-naïve CLL patients for the fixed-duration treatment combination of acalabrutinib plus venetoclax (with or without obinutuzumab) according to routine clinical practice from the EMA approval (i.e., 2 June 2025) (cohort 2).

Decision to administer acalabrutinib must be made and documented prior to inclusion into the study and must follow local clinical practice.

  • Informed consent (for alive patients).

Exclusion Criteria:

  • Enrolled in any clinical trial during acalabrutinib treatment.
  • Patients who are unable to understand the study and its questionnaires due to insufficient knowledge of the Spanish language or their health status.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: OTHER

Kohorten und Interventionen

Gruppe / Kohorte
Cohort 1

Patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit as per routine clinical practice, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression.

Cohort 2

Patients with first-line fixed-duration acalabrutinib use with venetoclax in routine clinical practice.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1).
Zeitfenster: 24 months after treatment initiation (cohort 1).

Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1).

In addition to this outcome measured in the overall cohort, it will also be assessed by the following factors:

  1. the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression),
  2. presence/absence of risk factors (i.e., del17p, TP53 mutation, and unmutated IGHV).
  3. cardiovascular comorbidities (yes/no).
24 months after treatment initiation (cohort 1).
Real-world overall response rate (rwORR) achieved until the end of the observational period for first-line fixed duration acalabrutinib therapy (cohort 2)
Zeitfenster: From fixed-duration acalabrutinib start to the start date of a subsequent line therapy or study end date (cohort 2), assessed up to 25 months after the inclusion of the last patient in the cohort 2.

rwORR (i.e., the proportion of patients that achieved complete or partial response) achieved until the end of the observational period for first-line fixed-duration acalabrutinib therapy as assessed by the treating physician (cohort 2). Complete response may include complete response, complete response with incomplete marrow recovery, or unconfirmed complete response (marrow biopsy not performed). Partial response may include partial response, or partial response with lymphocytosis. The rwORR will be assessed by the treating physician in routine clinical practice, including the use or not of the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. The end of observational period for first-line fixed-duration combinations of acalabrutinib is defined as the start date of a subsequent line therapy or study end date, whichever comes first.

From fixed-duration acalabrutinib start to the start date of a subsequent line therapy or study end date (cohort 2), assessed up to 25 months after the inclusion of the last patient in the cohort 2.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Acalabrutinib±venetoclax doses (cohorts 1 and 2).
Zeitfenster: At start date and subsequent dose adjustments during acalabrutinib±venetoclax administration assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Acalabrutinib±venetoclax doses (e.g., starting does and dose adjustments), overall (cohorts 1 and 2) and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

In cohort 2, doses (e.g., starting dose, dose adjustments, maximum dose achieved) and reasons for changes within the acalabrutinib±venetoclax fixed-duration regimen will also be described globally and for each drug separately, as well as the time to reach the maximal dose.

At start date and subsequent dose adjustments during acalabrutinib±venetoclax administration assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
Patients with acalabrutinib±venetoclax dose adjustments (n, %), temporary interruptions (n, %), and permanent discontinuations (n, %) (cohorts 1 and 2).
Zeitfenster: From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Acalabrutinib±venetoclax dose adjustments, temporary interruptions, and permanent discontinuations, overall (cohorts 1 and 2) and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

In patients with regimen modifications within cohort 2, the proportion of patients with these regimen modifications and the time from treatment initiation to the regimen modification within same line therapy prior to progression (e.g., treatment duration and number of cycles prior to the modification, and reason for the modification). In cohort 2, temporary interruptions, permanent discontinuations, and their reasons for changes within the acalabrutinib±venetoclax fixed-duration regimen will also be described globally and for each drug separately, as well as the proportion of patients requiring dose reductions after achieving maximum dose.

From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
Treatment duration in months (cohorts 1 and 2).
Zeitfenster: From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Treatment duration (cohorts 1 and 2), overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

In cohort 2, also median number of completed cycles and the proportion of patients who complete 14 cycles.

Baseline patient characteristics associated with treatment duration in multivariate analyses, overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
Treatment adherence according to the percentage of days covered (PDC) while receiving acalabrutinib (cohort 1).
Zeitfenster: From acalabrutinib start to acalabrutinib end, assessed up to 32 months of prospective study follow-up (cohort 1).

Treatment adherence according to the percentage of days covered (PDC) while receiving acalabrutinib, overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1).

The PDC will be based on data available on acalabrutinib treatment in pharmacy records, and defined as the percentage of days a patient has the medication available in a given period of time:

PDC (%)=(No.days covered)/(No.days of interest)×100

From acalabrutinib start to acalabrutinib end, assessed up to 32 months of prospective study follow-up (cohort 1).
TTNT (i.e., the time from the date of first dose of acalabrutinib to the first dose of the next treatment for CLL, or death from any cause) (cohorts 1 and 2).
Zeitfenster: From the date of first dose of acalabrutinib to first dose of next CLL treatment or death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

TTNT (i.e., the time from the date of first dose of acalabrutinib to the first dose of the next treatment for CLL, or death from any cause [i.e. deaths are not censored]), overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

From the date of first dose of acalabrutinib to first dose of next CLL treatment or death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
OS (i.e., the time from the date of first dose of acalabrutinib to death from any cause) (cohorts 1 and 2).
Zeitfenster: From the date of first dose of acalabrutinib to death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

OS (i.e., the time from the date of first dose of acalabrutinib to death from any cause), overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

From the date of first dose of acalabrutinib to death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
Adverse events that lead to acalabrutinib±venetoclax dose changes, temporary interruptions, or permanent discontinuation; that are considered serious during acalabrutinib±venetoclax treatment; and events of clinical interest (cohorts 1 and 2).
Zeitfenster: From acalabrutinib±venetoclax start to acalabrutinib±venetoxlax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Adverse events that lead to acalabrutinib±venetoclax dose changes, temporary interruptions, or permanent discontinuation.

Adverse events that are considered serious (including fatal events) during acalabrutinib±venetoclax treatment, globally and treatment related (when available).

Events of clinical interest (atrial fibrillation, hypertension, bleeding, infections, ventricular arrhythmias, hepatotoxicity, secondary primary malignancies, cytopenia, and pneumonitis) during acalabrutinib treatment, globally and treatment related (when available).

They will be described overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

From acalabrutinib±venetoclax start to acalabrutinib±venetoxlax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

11. Juli 2023

Primärer Abschluss (Geschätzt)

31. März 2029

Studienabschluss (Geschätzt)

31. März 2029

Studienanmeldedaten

Zuerst eingereicht

29. Juni 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

10. August 2023

Zuerst gepostet (Tatsächlich)

21. August 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

4. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

3. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • D8221R00003

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

IPD-Sharing-Zeitrahmen

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD-Sharing-Zugriffskriterien

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .